Pfizer considers selling its hospital drugs unit to cut debt and please activist investors.

Pfizer is exploring the sale of its hospital drugs unit, which includes antibiotics and sterile injectables, as part of efforts to divest non-core assets and reduce its $61.5 billion debt. This move follows pressure from activist investor Starboard Value and comes as Pfizer's CEO aims to reposition the company amid declining shares. The unit, worth potentially billions, could attract interest from pharmaceutical firms and private equity groups.

November 12, 2024
6 Articles